Clinical trials: Healthy Control Subjects
Health Adult Subjects
A TQTc Study for Omaveloxolone
This is a randomized, double blind, placebo and active (moxifloxacin open label) controlled study in healthy subjects to assess the effect of the supratherapeutic exposure of omaveloxolone on QTc interval.
- Trial name
- NCT05927649
- Testing
- Omaveloxolone, Moxifloxacin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Biogen
Bipolar Depression
Proof Of Mechanism Study To Determine Efficacy Of PF-04455242 In Blocking Spiradoline (PF-00345768) Stimulated Prolactin Release
This study will be a Proof of Mechanism (POM) study to establish evidence of central pharmacodynamic activity for PF 04455242, and will be a parallel group, randomized, double blind, sponsor open study conducted in healthy male…
- Trial name
- NCT00988949
- Testing
- PF-04455242, spiradoline
- Where
- Singapore
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers
A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects
First in human study to evaluate the safety, tolerability, and pharmacokinetics of PF-03716539. The potential of PF-03716539 to increase the concentrations of midazolam, darunavir and maraviroc will also be evaluated.
- Trial name
- NCT00783484
- Testing
- PF-03716539, Midazolam, Midazolam + PF-03716539 (100 mg)
- Where
- Belgium
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants
The purpose of this study is to evaluate the safety and tolerability of TAK-831 when administered as multiple oral doses at escalating dose levels in healthy participants.
- Trial name
- NCT03224325
- Testing
- TAK-831 Tablet T2, TAK-831 Suspension
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Neurocrine Biosciences
FXI
Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects
The purpose of this study is to evaluate safety, tolerability, PK, and PD of SAD of FXI-GalNAc-siRNA administered SC to healthy subjects.
- Trial name
- NCT05844293
- Testing
- FXI-GalNAc-siRNA
- Where
- 2 sites in United States, Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sirnaomics
Rhinitis
A Study to Investigate the Effect of SB-705498 on Chronic Cough
This study is designed to loook at the affect of oral SB-705498 on cough following an inhaled capsaicin challenge
- Trial name
- NCT01476098
- Testing
- SB-705498
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline
Healthy Volunteers, Safety
Single Centre, Double-blind, Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects
The purpose of the study is to assess safety and tolerability of AZD9819 following inhaled administration of single and multiple increasing doses, and to estimate the maximum dose that is tolerated in healthy people.
- Conditions
- Healthy Volunteers, Safety, Tolerability
- Trial name
- NCT01166698
- Testing
- AZD9819
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Participants
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects
Study E6742-A001-001 is a randomized, double-blind, placebo-controlled, single ascending dose study conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending oral doses…
- Trial name
- NCT03082235
- Testing
- E6742
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Heart Failure
A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Kidney Disease and in Age-, Weight- and Gender-matched Healthy Participants
Vericiguat (BAY1021189) is under development to treat heart failure, a condition in in which the heart has trouble pumping blood through the body.
- Trial name
- NCT04722484
- Testing
- Vericiguat (BAY1021189)
- Where
- Germany
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy Subjects, COVID-19 Pneumonia
Jing Si Herbal Tea for Long-Coronavirus Disease(COVID) Gut-brain Interaction
Dyspepsia refers to chronic or recurrent upper gastrointestinal symptoms. According to the Rome IV criteria, functional dyspepsia (FD) symptoms included meal related fullness, early satiation, epigastric pain or burning which are…
- Conditions
- Healthy Subjects, COVID-19 Pneumonia, Irritable Bowel Syndrome, Functional Gastrointestinal Disorders
- Trial name
- NCT05668104
- Testing
- Jing Si Herbal Tea Liquid Packet
- Where
- Taiwan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Buddhist Tzu Chi General Hospital
Healthy
Impact of Butyricicoccus Pullicaecorum in Healthy Subjects
During this project the safety, tolerability and effect on gut microbiota of oral administration of Butyricicoccus pullicaecorum was investigated in healthy human volunteers by a placebo-controlled cross-over randomized study.
- Trial name
- NCT02477033
- Testing
- Butyricicoccus pullicaecorum 25-3T, Maltodextrin
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- KU Leuven
Healthy Volunteers
Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers
The primary objective of the study is to compare the safety and tolerability of subcutaneous (SC) and intravenous (IV) doses of evinacumab in healthy Japanese and Caucasian subjects.
- Trial name
- NCT03146416
- Testing
- Evinacumab
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Diabetes Mellitus, Type 2
A Study of the Efficacy and Safety of Supaglutide in Healthy Participants
This study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the investigational drug Supaglutide proposed dosing once (or twice) weekly in Chinese healthy subjects.
- Trial name
- NCT03745885
- Testing
- Supaglutide injection
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Healthy Subjects
Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects
This Phase 1, randomized, three period, placebo- and positive-controlled,double-blind, double-dummy, crossover study will be performed with approximately 80 healthy male and female subjects.
- Trial name
- NCT00672399
- Testing
- exenatide, Moxifloxacin
- Where
- 2 sites in United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Health Subjects
A Study of A4368 in Healthy Subjects
A4368 is the autophagy activator that is being developed for the treatment of nonalcoholic steatohepatitis. The goal of the study is to assess the safety, tolerability, and pharmacokinetics in healthy subjects.
- Trial name
- A4368 (NCT04932252)
- Where
- South Korea
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Autophagy Sciences, Inc.
Healthy
A Study of LY3316531 in Healthy Participants
The purpose of this study is to assess study drug activity by giving LY3316531 or placebo into a vein in the arm and then measuring blood flow of the skin, after capsaicin is applied to skin's surface.
- Trial name
- NCT03611608
- Testing
- LY3316531
- Where
- Belgium
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Cystic Fibrosis
A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects
This is a first in human study of ETD001 a new drug being developed for the treatment of cystic fibrosis. The study is a randomised, placebo-controlled, double-blind interventional study to assess the safety, tolerability and…
- Trial name
- NCT04926701
- Testing
- ETD001 single dose, ETD001 multiple twice daily doses, ETD001 multiple once daily doses
- Where
- United Kingdom
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Enterprise Therapeutics Ltd
Nipah Virus Infection
A Phase 1 Study to Evaluate Safety & Immunogenicity of RVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects
A Phase 1 Study to Evaluate the Safety and Immunogenicity of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects
- Trial name
- NCT05178901
- Testing
- PHV02
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Public Health Vaccines LLC
Asthma
GSK2239633 FTIH Study
The purpose of this first time into human study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633 in healthy male subjects.
- Trial name
- NCT01371812
- Testing
- GSK2239633
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Ulcerative Colitis, Crohn's Disease
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
To assess the safety and tolerability of multiple subcutaneous doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
- Trial name
- NCT01290042
- Testing
- AMG 181
- Where
- 8 sites in United States, Australia
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Amgen